Home » Rare Disease Drug Boom Bolstered By FDA Orphan Drug Grant Program
Rare Disease Drug Boom Bolstered By FDA Orphan Drug Grant Program
The FDA on Oct. 21 awarded 15 grants totaling more than $14 million to various research organizations — and one drugmaker — to spur development of new treatments for rare diseases, the latest signal the agency wants to prime the orphan drug pipeline. Boston-based start-up Alkeus Pharmaceuticals was the only drugmaker to receive a grant from the agency, getting $167,000 to fund a Phase I study of ALK001 to treat the genetic eye disorder known as Stargardt disease.
Washington Drug Letter
Washington Drug Letter
Upcoming Events
-
07May
-
14May
-
30May